No immediate trading signal; this is a standard initial ownership disclosure. Monitor for actual option exercises or future insider transactions, which could signal confidence or liquidity needs.
Price Chart
Executive Summary
Philip A. Serlin, CEO of BioLineRx Ltd., filed a Form 3 disclosing his beneficial ownership of employee stock options totaling 14,719,200 ordinary shares. All options were previously granted under the company's incentive plan, with most fully vested as of the filing date.
Key Facts
- Philip A. Serlin, CEO of BioLineRx Ltd., filed initial statement of beneficial ownership on Form 3
- Reporting date for ownership is March 18, 2026
- Total reported options: 14,719,200 ordinary shares across seven grants
- All options are under the 2003 Amended and Restated Share Incentive Plan
- Options have exercise prices ranging from $0.045 to $0.287 per share
- Most options are fully vested; 1,404,600 options from the September 6, 2023 grant remain unvested and will vest in five equal quarterly installments
- Shares are held via a trustee to qualify for tax benefits under Israeli Section 102
Financial Impact
Potential future dilution of up to 14,719,200 shares if all options are exercised, though no immediate financial impact as this is a routine insider ownership filing
Risk Factors
- Potential share dilution if large number of options are exercised
- Concentration of insider ownership could affect corporate governance dynamics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001178913-26-001790 |
| Document: 0001178913-26-001790-index.html | 0001178913-26-001790 |
| Document: 0001178913-26-001790.txt | 0001178913-26-001790 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.04 | awaiting T+20 | — | $2.03 (−0.49%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.03 (+12.50%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.03 (−16.46%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.03 (−21.00%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.03 (−32.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers